MTNR1B — When You Eat Matters More Than What You Eat
The MTNR1B gene encodes melatonin receptor 1B | One of two G-protein-coupled
receptors for melatonin (MT1 and MT2). MT2 (MTNR1B) is expressed in the brain,
retina, and — critically — in pancreatic beta cells (MT2), a receptor found
not only in the brain but also on the insulin-producing beta cells of the
pancreas. This dual role places MTNR1B at the crossroads of two fundamental
biological systems: the circadian clock and glucose metabolism.
The rs10830963 variant sits in an intron of MTNR1B and is one of the strongest
GWAS | Genome-wide association study: an approach that scans the entire genome
of thousands of people to find genetic variants associated with a trait or
disease hits for fasting glucose levels ever identified, reaching a
significance of P = 3.2 x 10-50 in the original discovery. The G allele — carried
by roughly 28% of Europeans and up to 45% of East Asians — extends the duration of
melatonin signaling in pancreatic beta cells, impairing their ability to release
insulin in response to glucose. This makes it one of the most actionable
chrono-nutrition | The study of how the timing of food intake interacts with
circadian biology to affect metabolic health SNPs: for G carriers, when you
eat may matter as much as what you eat.
The Mechanism
Melatonin is the hormone of darkness — it rises in the evening, peaks during the
night, and falls before dawn. When melatonin binds MT2 receptors on pancreatic
beta cells, it activates inhibitory G-proteins | Gi proteins that reduce
intracellular cAMP levels, dampening the cell's ability to secrete insulin in
response to glucose (Gi), reducing cAMP and suppressing glucose-stimulated
insulin secretion. This is normally useful: it prevents insulin surges during
sleep when you are not eating.
The rs10830963 G allele increases MTNR1B expression in beta cells. More MT2
receptors mean stronger melatonin-mediated suppression of insulin secretion, and
Lane and colleagues | Lane JM et al. Impact of Common Diabetes Risk Variant in
MTNR1B on Sleep, Circadian, and Melatonin Physiology. Diabetes, 2016
showed that G carriers also have a 41-minute longer duration of elevated melatonin
and a 1.37-hour delayed melatonin offset in the morning. The result is a wider
window during which insulin secretion is suppressed — a window that overlaps with
meal times if you eat late at night or early in the morning.
The Evidence
The original GWAS discovery | Prokopenko I et al. Variants in MTNR1B influence
fasting glucose levels. Nat Genet, 2009
across 36,610 individuals found each G allele raises fasting glucose by
0.07 mmol/L (P = 3.2 x 10-50). A simultaneous study by
Lyssenko and colleagues | Lyssenko V et al. Common variant in MTNR1B associated
with increased risk of type 2 diabetes and impaired early insulin secretion. Nat
Genet, 2009 confirmed that the risk
genotype impairs early insulin response to both oral and intravenous glucose, with
MTNR1B expression elevated in islets of risk carriers.
A large replication study | Sparsø T et al. G-allele of intronic rs10830963 in
MTNR1B confers increased risk of impaired fasting glycemia and type 2 diabetes.
Diabetes, 2009 of 19,605 Europeans
found the G allele increases impaired fasting glycemia risk with OR 1.64
(P = 5.5 x 10-11). In the UK Biobank | Tan X et al. Associations between
chronotype, MTNR1B genotype and risk of type 2 diabetes in UK Biobank. J Intern
Med, 2020 analysis of 337,083
participants, CG carriers had OR 1.10 and GG carriers OR 1.21 for type 2 diabetes
compared to CC.
The meal-timing dimension was demonstrated in a randomized crossover trial |
Garaulet M et al. Late dinner impairs glucose tolerance in MTNR1B risk allele
carriers: a randomized, cross-over study. Clin Nutr, 2017:
eating late (when melatonin is elevated) significantly impaired glucose tolerance
in G carriers but not in CC individuals. A larger follow-up | Lopez-Minguez J
et al. Interplay of Dinner Timing and MTNR1B Type 2 Diabetes Risk Variant on
Glucose Tolerance and Insulin Secretion. Diabetes Care, 2022
with 845 participants confirmed that late dinner (1 hour before bed vs. 4 hours)
produced 3.5-fold higher melatonin levels, 6.7% lower insulin area under the
curve, and 8.3% higher glucose AUC — with significantly stronger effects in G
carriers.
Practical Implications
This is one of the most actionable SNPs in the glucose-metabolism space because
the intervention is simple: eat dinner earlier. For G carriers, the overlap of
high melatonin and high glucose from a late meal is what drives the impairment —
shifting the last meal to at least 3-4 hours before bedtime substantially
reduces this effect.
Morning eating may also matter. Lane et al. found that the T2D risk in G carriers
was amplified in early risers, likely because these individuals wake while
melatonin is still elevated. Having breakfast 1-2 hours after waking (rather
than immediately) may help avoid the melatonin-glucose collision for early-rising
G carriers.
Weight management is also relevant: the POUNDS Lost trial | Huang T et al.
A circadian rhythm-related MTNR1B genetic variant modulates the effect of
weight-loss diets on changes in adiposity and body composition. Am J Clin Nutr,
2018 found that the G allele
modulates the effect of diet composition on weight loss, with G carriers losing
more weight on low-fat diets and gaining more body fat on high-fat diets.
Interactions
MTNR1B rs10830963 interacts with other type 2 diabetes risk loci. Carriers of
the G allele here who also carry the TCF7L2 rs7903146 risk allele (T) face
compounded diabetes risk through independent but converging pathways — MTNR1B
impairing insulin secretion timing, TCF7L2 impairing beta cell development and
incretin signaling. Both SNPs are independently actionable: meal timing for
MTNR1B, dietary fat moderation for TCF7L2.
The CLOCK gene variant rs1801260 influences chronotype (morning vs. evening
preference), which in turn affects when melatonin rises and falls. An evening
chronotype combined with the MTNR1B G allele could extend the overlap between
elevated melatonin and late eating, though direct evidence for this specific
gene-gene interaction remains limited.
All Genotypes
Normal melatonin-insulin timing — no special meal timing needed
You carry two copies of the C allele, which is the most common genotype worldwide — about 52% of people share it. Your MTNR1B expression in pancreatic beta cells is at baseline levels, meaning melatonin suppresses insulin secretion at the expected rate and duration. In clinical trials, CC individuals showed no significant impairment in glucose tolerance when eating late versus early. Your insulin response to meals is not meaningfully affected by the timing of melatonin rise and fall.
One copy of the risk allele — meal timing moderately affects glucose control
You carry one copy of the G allele, giving you an intermediate level of MTNR1B expression in your pancreatic beta cells. This is the second most common genotype, found in about 40% of people globally. In the UK Biobank analysis, CG carriers had a 10% increased risk of type 2 diabetes compared to CC (OR 1.10). Your melatonin signaling duration is moderately extended, meaning late meals — eaten when melatonin is already rising — may impair your glucose tolerance more than in CC individuals.
Two copies of the risk allele — meal timing significantly affects glucose control and diabetes risk
You carry two copies of the G allele, which is the least common genotype — found in about 8% of people globally, though it reaches roughly 20% in East Asian populations. Your MTNR1B expression is substantially elevated, meaning melatonin suppresses your insulin secretion more strongly and for a longer duration than in most people. In the UK Biobank study of 337,083 participants, GG carriers had a 21% increased risk of type 2 diabetes compared to CC (OR 1.21). However, this risk is strongly modifiable by meal timing — clinical trials show that eating earlier virtually eliminates the genotype-specific glucose impairment.